Login / Signup

The future of microfluidics in immune checkpoint blockade.

Jonathan BrionesWilfred EspulgarShohei KoyamaHyota TakamatsuEiichi TamiyaMasato Saito
Published in: Cancer gene therapy (2020)
Recent advances in microfluidic techniques have enabled researchers to study sensitivities to immune checkpoint therapy, to determine patients' response to particular antibody treatment. Utilization of this technology is helpful in antibody discovery and in the design of personalized medicine. A variety of microfluidic approaches can provide several functions in processes such as immunologic, genomic, and/or transcriptomic analysis with the aim of improving the efficacy and coverage of immunotherapy, particularly immune checkpoint blockade (ICB). To achieve this requires researchers to overcome the challenges in the current state of the technology. This review looks into the advancements in microfluidic technologies applied to researches on immune checkpoint blockade treatment and its potential shift from proof-of-principle stage to clinical application.
Keyphrases
  • high throughput
  • single cell
  • circulating tumor cells
  • end stage renal disease
  • ejection fraction
  • stem cells
  • gene expression
  • prognostic factors
  • combination therapy
  • dna methylation